• Mashup Score: 0
    Sarcoidosis Explained - 7 month(s) ago

    Frank Rivera of Stronger Than Sarcoidosis, Sarcoidosis of Long Island, and a patient himself, discusses this rare immunologic condition.

    Source: CheckRare.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CheckRare
      CheckRare

      Frank Rivera of Stronger Than Sarcoidosis and Sarcoidosis of Long Island, two patient advocacy groups focused on raising awareness and research, discusses the rare disease #checkrare #rarediseases #sarcoidosis @SarcoidosisUK @rarediseasesnet https://t.co/2NGJEUKTL5

  • Mashup Score: 3
    Pri-Med | Sarcoidosis in the Lungs: What... - 7 month(s) ago

    Already listened on another platform? 0.25 AMA PRA Category 1 Credits ™, 0.25 ABIM MOC or 0.25 AANP, including 0.25 AANP Pharm The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute. Mridu Gulati, MD, MPH: Speaker for Boehringer Ingelheim. Advisor for CDC/NIOSH. Researcher for Boehringer Ingelheim and Bristol Myers Squibb. George A. Mensah, MD: No relevant financial relationships disclosed. Charles Vega, MD, FAAFP (Moderator):

    Source: www.pri-med.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of NHLBI_Translate
      NHLBI_Translate

      .#NHLBI curriculum. #PrimaryCare: Earn CME credit via @PriMedCME podcast presented with @StopSarcoidosis on what to know about #sarcoidosis in the #lungs. #ImpSci @NIH. Speakers: Dr. George Mensah at @NIH_NHLBI & Dr. Mridu Gulati at @YaleMed. Listen here: https://t.co/BA63h3IpbS https://t.co/yzJcy9mqTp

  • Mashup Score: 0
    Efzofitimod safe, may improve clinical outcomes in patients with sarcoidosis - 8 month(s) ago

    Among patients with pulmonary sarcoidosis, efzofitimod was safe through 24 weeks, and it improved measures of lung function and quality of life when given at a higher dosage, according to study results published in CHEST.“Sarcoidosis is an area of unmet need, with no FDA-approved therapies in over 60 years,” Daniel A. Culver, DO, chair of the department of pulmonary medicine at

    Source: www.healio.com
    Categories: Latest Headlines, Pulmonology
    Tweet Tweets with this article
    • Profile photo of HealioPulm
      HealioPulm

      ICYMI: “[This study] shows that the neuropilin 2 receptor is a potential therapy target in #sarcoidosis #inflammation, and that using this pathway may be a way to treat sarcoidosis," Daniel A. Culver, DO, at @ClevelandClinic, told Healio. https://t.co/gjZYzCW0V2

Load More